Literature DB >> 9005894

Histopathologic study of veins in steroid treated rabbits.

T Nishimura1, T Matsumoto, M Nishino, K Tomita.   

Abstract

Although arterial factors have been regarded as playing an important role in the pathogenesis of osteonecrosis, more attention has been given to venous factors because steroids cause an increase in the intraosseous pressure despite a decrease in blood flow in the femoral head. The authors examined changes in the veins of steroid treated rabbits. Forty rabbits were used: 30 rabbits (the steroid treated group) were injected with methylprednisolone acetate (4 mg/kg) weekly and 10 rabbits (the control group) were treated without steroids. The veins around the femoral head, ear veins, femoral veins, and inferior vena cava were obtained after 8 weeks of treatment, and the specimens were examined by immunohistochemical staining and electron microscopy. In the steroid treated group, proliferation of foam cells was observed in the intima of the vein in 7 of 30 rabbits. Immunohistochemical studies, using monoclonal antibodies for smooth muscle cells and macrophages, showed that the foam cells were derived from smooth muscle cells. Electron microscopy showed damage to the endothelial cells and smooth muscle cells. These results indicated that corticosteroids damaged the venous system. It is suggested that steroid induced disturbance of the draining veins causes stasis and that steroids are an important factor in osteonecrosis of the femoral head.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005894

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

Review 1.  Osteonecrosis of the Hip: A Primer.

Authors:  Michelle J Lespasio; Nipun Sodhi; Michael A Mont
Journal:  Perm J       Date:  2019

Review 2.  Prevention and treatment of systemic glucocorticoid side effects.

Authors:  Siamak Moghadam-Kia; Victoria P Werth
Journal:  Int J Dermatol       Date:  2010-03       Impact factor: 2.736

3.  Osteonecrosis of Bilateral Distal Femurs in a Pregnant Patient Following Antenatal Betamethasone.

Authors:  Rafal S Ali; Hussein Al-Sudani; Irene J Tan
Journal:  Cureus       Date:  2022-03-01

4.  Effects of glucocorticoid on adipocyte size in human bone marrow.

Authors:  Masaru Kitajima; Masamori Shigematsu; Kenji Ogawa; Hajime Sugihara; Takao Hotokebuchi
Journal:  Med Mol Morphol       Date:  2007-09-18       Impact factor: 2.309

5.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

6.  Genome-wide association scans for idiopathic osteonecrosis of the femoral head in a Korean population.

Authors:  Seung-Hoon Baek; Kang-Il Kim; Kyung-Sik Yoon; Tae-Ho Kim; Shin-Yoon Kim
Journal:  Mol Med Rep       Date:  2016-12-14       Impact factor: 2.952

7.  Role of Junction-Mediating and Regulatory Protein in the Pathogenesis of Glucocorticoid-Induced Endothelial Cell Lesions.

Authors:  Wei Zuo; Wan-Shou Guo; Hua-Chen Yu; Pei Liu; Qi-Dong Zhang
Journal:  Orthop Surg       Date:  2020-05-04       Impact factor: 2.071

Review 8.  Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head.

Authors:  Qiankun Zhang; Jin L V; Lie Jin
Journal:  J Int Med Res       Date:  2017-05-01       Impact factor: 1.671

9.  Decreased angiogenic and increased apoptotic activities of bone microvascular endothelial cells in patients with glucocorticoid-induced osteonecrosis of the femoral head.

Authors:  Huachen Yu; Pei Liu; Wei Zuo; Xiaowei Sun; Hongzhi Liu; Feifan Lu; Wanshou Guo; Qidong Zhang
Journal:  BMC Musculoskelet Disord       Date:  2020-04-29       Impact factor: 2.362

10.  Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.

Authors:  Fatemeh Valamanesh; Marianne Berdugo; Florian Sennlaub; Michèle Savoldelli; Cyndie Goumeaux; Marianne Houssier; Jean-Claude Jeanny; Alicia Torriglia; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.